New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis

Why It Matters

The results could shift the treatment paradigm for dermatomyositis from chronic steroid reliance to a targeted oral therapy, offering faster, sustained disease control. Successful approval would also validate dual TYK2/JAK1 inhibition for autoimmune disorders.

Key Takeaways

• Brepocitinib 30 mg improved TIS by 15.3 points vs placebo
• Primary endpoint met; benefits from week 4 through week 52
• Steroid use halved; twice as many patients tapered corticosteroids
• Serious infections higher with brepocitinib but resolved with care
• FDA granted priority review; PDUFA decision expected Q3 2026

Pulse Analysis

Dermatomyositis, a rare inflammatory myopathy marked by muscle weakness and painful skin eruptions, has long been managed with high‑dose systemic corticosteroids and broad immunosuppressants. While these agents can blunt disease activity, they carry substantial risks such as infection, osteoporosis, and metabolic complications, leaving patients with limited long‑term options. The emergence of targeted kinase inhibitors promises a more precise approach, but few have demonstrated both efficacy and steroid‑sparing benefits in rigorous Phase 3 studies. In this context, Priovant’s oral TYK2/JAK1 blocker brepocitinib entered the VALOR trial with high expectations from both clinicians and investors.

The VALOR study enrolled 241 adults across 90 sites and randomized participants to brepocitinib 30 mg, 15 mg, or placebo. At week 52, the 30 mg cohort achieved a 15.3‑point advantage in the composite Total Improvement Score, surpassing the pre‑specified threshold for clinical relevance (P < 0.001). Benefits were evident as early as week 4 and spanned muscle strength, skin disease activity, functional disability, and quality‑of‑life measures. Importantly, more than half of responders cut prednisone use to ≤ 2.5 mg/day, highlighting a genuine steroid‑sparing effect. Safety signals showed a modest rise in serious infections with active treatment, yet these events resolved and overall discontinuation rates were lower than placebo.

The U.S. Food and Drug Administration has placed brepocitinib’s New Drug Application under priority review, targeting a third‑quarter 2026 decision, a timeline that could accelerate market entry for a disease with unmet therapeutic need. If approved, brepocitinib would join a growing class of selective TYK2 inhibitors, potentially opening doors for similar strategies in other autoimmune indications such as non‑infectious uveitis and cutaneous sarcoidosis—areas already advancing in Priovant’s pipeline. For investors, the data reinforce Roivant’s ‘Vant’ model of rapid development, while clinicians may soon have an oral, disease‑modifying option that reduces reliance on toxic steroids.